Personalis, Inc. (PSNL) is a genomics company specializing in advanced cancer genomic tests and services for precision oncology and personalized testing. The company provides genomic testing services to pharmaceutical companies, healthcare providers, research institutions, and government entities. Its offerings include tumor profiling, diagnostic tests, and genomic sequencing services designed to support clinical trials, drug development, and cancer patient care.
- Pharma Tests and Services - Provides testing services and data analytics for clinical trials and research to pharmaceutical companies, supporting their drug development programs.
- Enterprise Sales - Offers tumor profiling and diagnostic tests directly to other businesses, such as Natera, for integration into their products.
- Population Sequencing - Delivers genomic sequencing services and data analytics to support large-scale genetic research programs, including initiatives like the VA Million Veterans Program.
- Clinical Diagnostic - Supplies comprehensive tumor profiling tests and ultra-sensitive, tumor-informed diagnostic tests ordered by healthcare providers for cancer patients.
- Other - Sells genomic tests and analytics to universities and non-profits for research and educational purposes.
You might also like
| Name | Position | External Roles | Short Bio | |
|---|---|---|---|---|
Christopher Hall ExecutiveBoard | Chief Executive Officer and President | Christopher Hall has served as the CEO and President of Personalis, Inc. since March 2023 and is a member of the Board of Directors. Previously, he led the Diagnostics Business as Senior Vice President starting in October 2022. | View Report → | |
Aaron Tachibana Executive | Chief Financial Officer | Aaron Tachibana has been the CFO of Personalis, Inc. since March 2019 and was appointed COO in March 2023, after serving as interim CEO from December 2022 to March 2023. Prior to PSNL, he held executive roles at Lumentum Holdings Inc., JDS Uniphase Corp., and Pericom Semiconductor Corp.. | ||
Richard Chen Executive | Executive Vice President, Research and Development, and Chief Medical Officer | Richard Chen is the Executive Vice President, Research and Development, and Chief Medical Officer at PSNL since March 2023, having previously served as Senior Vice President, R&D and Chief Scientific Officer. He brings extensive expertise in genomics and medical research, and has served on the clinical faculty at Stanford University School of Medicine since September 2011. | ||
Stephen Moore Executive | Senior Vice President and Chief Legal Officer | Stephen Moore has served as Senior Vice President and Chief Legal Officer at PSNL since February 2024, and previously served as Vice President and General Counsel from April 2020 to February 2024. |
- Given the revenue decline in Q2 driven by delays from major customers like Natera and Moderna, what specific measures are you implementing to stabilize this dependency and reduce future revenue volatility?
- With clinical revenue guidance tightened from $10M to $6M this quarter, how are you adjusting your patient uptake and reimbursement strategy in response to evolving Medicare timelines?
- Since MRD test volume growth is strongly tied to your partnership with Tempus, how will you ensure this collaboration doesn’t limit your expansion into non-Tempus accounts or affect your independence in negotiating reimbursement policies?
- Faced with downward pressure on gross margins due to unreimbursed clinical test costs, what operational or pricing strategies are you deploying to improve margins once Medicare coverage is achieved?
- In light of policy headwinds delaying biopharma project revenues and creating uncertainty in translational research, how are you planning to align full-year revenue guidance with these disruptions while still aggressively driving MRD volume growth?
Competitors mentioned in the company's latest 10K filing.
| Company | Description |
|---|---|
Adela, Inc. | This company is listed as one of the principal competitors employing various approaches to produce information similar to what the company generates for its customers. |
BostonGene Corporation | This organization is identified as a competitor in the field of genomic profiling and cancer diagnostics. |
Caris Life Sciences, Inc. | This company is mentioned as a competitor in the genomic profiling and cancer diagnostics market. |
DELFI Diagnostics, Inc. | This company is noted as a competitor in the genomic profiling and cancer diagnostics space. |
This organization is listed as a competitor in the genomic profiling and cancer diagnostics industry. | |
Foresight Diagnostics Inc. | This company is identified as a competitor in the genomic profiling and cancer diagnostics market. |
Foundation Medicine, Inc. | This company is mentioned as a competitor in the genomic profiling and cancer diagnostics field. |
Freenome, Inc. | This organization is listed as a competitor in the genomic profiling and cancer diagnostics industry. |
This company is identified as a competitor in the genomic profiling and cancer diagnostics market. | |
Geneseeq Technology Inc. | This organization is noted as a competitor in the genomic profiling and cancer diagnostics space. |
This company is mentioned as a competitor in the genomic profiling and cancer diagnostics field. | |
This organization is listed as a competitor in the genomic profiling and cancer diagnostics industry. | |
Haystack Oncology, Inc. | This company, acquired by Quest Diagnostics Incorporated in June 2023, is identified as a competitor in the genomic profiling and cancer diagnostics market. |
This organization is noted as a competitor in the genomic profiling and cancer diagnostics space. | |
MedGenome Inc. | This company is mentioned as a competitor in the genomic profiling and cancer diagnostics field. |
This organization is listed as a competitor in the genomic profiling and cancer diagnostics industry. | |
This company is identified as a competitor and also a significant customer, accounting for 30% of the company's revenue in 2024. | |
This organization is noted as a competitor in the genomic profiling and cancer diagnostics space. | |
Novogene Corporation | This company is mentioned as a competitor in the genomic profiling and cancer diagnostics field. |
Predicine, Inc. | This organization is listed as a competitor in the genomic profiling and cancer diagnostics industry. |
Roche Molecular Systems, Inc. | This company is identified as a competitor in the genomic profiling and cancer diagnostics market. |
SAGA Diagnostics AB | This organization is noted as a competitor in the genomic profiling and cancer diagnostics space. |
Tempus | This company is mentioned as both a competitor and a partner, with agreements to co-commercialize products and provide services. |
This organization is listed as a competitor in the genomic profiling and cancer diagnostics industry. | |
This company develops next-generation sequencing platforms and clinical oncology kits, competing in genomic profiling for biopharmaceutical research and development applications. | |
This organization develops next-generation sequencing platforms and clinical oncology kits, competing in genomic profiling for biopharmaceutical research and development applications. |
| Customer | Relationship | Segment | Details |
|---|---|---|---|
Natera, Inc. | Advanced tumor analysis for MRD tests | Enterprise Sales | 2024 rev: 30% , 2023 rev: 43% , 2024 A/R: 13% , 2023 A/R: 36% |
Moderna, Inc. | Genomic testing to support personalized cancer therapies | Pharma Tests & Services | 2024 rev: 28% , 2023 rev: 5% , 2024 A/R: <10% |
VA MVP | Whole genome sequencing and data analytics for research | Population Sequencing | 2024 rev: 9% , 2023 rev: 13% , 2024 A/R: <10% |
Merck & Co. | Not specified in detail | All | 2024 A/R: 31% , Rev: N/A |
Pfizer Inc. | Not specified in detail | All | 2024 A/R: 25% , Rev: N/A |
Recent press releases and 8-K filings for PSNL.
- Personalis reported Q2 2025 revenue of $17.2 million, a 24% decrease compared to Q2 2024, and a net loss of $20.1 million.
- The company delivered 3,478 clinical tests in Q2 2025, representing a 59% sequential increase over Q1 2025, demonstrating accelerating physician adoption of the NeXT Personal® platform.
- Personalis updated its full-year 2025 guidance, reducing total company revenue expectations to a range of $70 to $80 million (from $80 to $90 million) and increasing the projected net loss to approximately $85 million (from $83 million).
- Personalis has expanded its strategic collaboration with Tempus AI, Inc. to include colorectal cancer (CRC) as a new indication for its NeXT Personal® ultra-sensitive, tumor-informed minimal residual disease (MRD) test.
- This expansion means the NeXT Personal test will now cover four major cancer types: breast, lung, and colorectal cancers, and solid tumor immunotherapy monitoring.
- The agreement's term has been extended to November 2029, and Tempus's exclusivity for all four indications is lengthened through 2028.
- The addition of CRC follows compelling interim analysis results from the VICTORI study, and colorectal cancer affects over 150,000 new patients in the U.S. annually.